What is Morphle Labs?
Morphle Labs Inc. is at the forefront of digital pathology innovation, specializing in the development of advanced solutions designed to revolutionize cancer diagnostics. Their product suite includes high-throughput robotic microtomes, such as the Robotome, and AI-enabled microscope slide scanners, like the MorphoLens. These technologies are engineered to enhance diagnostic accuracy and efficiency for healthcare providers and research institutions globally. By focusing on customer success and offering robust support systems, Morphle Labs facilitates the seamless integration of their cutting-edge digital pathology tools into existing healthcare workflows, supporting telepathology and digital slide storage initiatives.
How much funding has Morphle Labs raised?
Morphle Labs has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2025): $5M with participation from Inflexor
Key Investors in Morphle Labs
Inflexor
Inflexor Ventures is a technology-focused venture capital firm that invests in next-generation tech startups led by innovative founding teams. The firm aims to support audacious founders who are building companies that will define the future, with a strong emphasis on science, engineering, and technology.
What's next for Morphle Labs?
With the recent major strategic investment, Morphle Labs is poised for significant expansion and further development of its AI-driven digital pathology solutions. This capital infusion is expected to accelerate the company's growth trajectory, enabling enhanced research and development, broader market penetration, and the scaling of its operations. The strategic backing suggests a strong market validation for Morphle Labs' technology, positioning them to further solidify their role in advancing diagnostic capabilities within the healthcare industry.
See full Morphle Labs company page
